Sandra García-Padilla1, Miguel Angel Duarte-Vázquez2, Karla Elena Gonzalez-Romero3, María Del Carmen Caamaño4,5, Jorge L Rosado6,7. 1. Cindetec A.C, Parque Industrial Querétaro, Jurica 122, Santiago de Querétaro, C.P. 76220, Qro, Mexico. sgarcia@cindetecresearch.org. 2. Nucitec S.A. de C.V, Santiago de Querétaro, Mexico. mduarte@nucitec.com. 3. Cindetec A.C, Parque Industrial Querétaro, Jurica 122, Santiago de Querétaro, C.P. 76220, Qro, Mexico. kareladonai@hotmail.com. 4. Cindetec A.C, Parque Industrial Querétaro, Jurica 122, Santiago de Querétaro, C.P. 76220, Qro, Mexico. maria.delcarmen.caamano@uaq.mx. 5. Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico. maria.delcarmen.caamano@uaq.mx. 6. Cindetec A.C, Parque Industrial Querétaro, Jurica 122, Santiago de Querétaro, C.P. 76220, Qro, Mexico. jlrosado@prodigy.net.mx. 7. Universidad Autónoma de Querétaro, Santiago de Querétaro, Mexico. jlrosado@prodigy.net.mx.
The original version of this article [1] unfortunately contained a mistake. The formula concentration described in the “Treatments” section was provided incorrectly. The corrected text is available below:“The SBCG1 treatment was a solution with sodium bicarbonate and calcium gluconate, both at a concentration of 0.75 % (w/v); and SBCG2 had the same concentration of sodium bicarbonate than SBCG1, while the concentration of calcium gluconate was 1.5 % (w/v).
Authors: Sandra García-Padilla; Miguel Angel Duarte-Vázquez; Karla Elena Gonzalez-Romero; María del Carmen Caamaño; Jorge L Rosado Journal: BMC Musculoskelet Disord Date: 2015-05-13 Impact factor: 2.362